These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15529261)

  • 1. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.
    Montefiori DC; Metch B; McElrath MJ; Self S; Weinhold KJ; Corey L;
    J Infect Dis; 2004 Dec; 190(11):1962-9. PubMed ID: 15529261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
    Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
    Cleghorn F; Pape JW; Schechter M; Bartholomew C; Sanchez J; Jack N; Metch BJ; Hansen M; Allen M; Cao H; Montefiori DC; Tomaras GD; Gurunathan S; Eastman DJ; do Lago RF; Jean S; Lama JR; Lawrence DN; Wright PF;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):222-30. PubMed ID: 17693888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
    Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
    Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.
    Wang S; Arthos J; Lawrence JM; Van Ryk D; Mboudjeka I; Shen S; Chou TH; Montefiori DC; Lu S
    J Virol; 2005 Jun; 79(12):7933-7. PubMed ID: 15919951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
    Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    Connor RI; Korber BT; Graham BS; Hahn BH; Ho DD; Walker BD; Neumann AU; Vermund SH; Mestecky J; Jackson S; Fenamore E; Cao Y; Gao F; Kalams S; Kunstman KJ; McDonald D; McWilliams N; Trkola A; Moore JP; Wolinsky SM
    J Virol; 1998 Feb; 72(2):1552-76. PubMed ID: 9445059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
    Russell ND; Graham BS; Keefer MC; McElrath MJ; Self SG; Weinhold KJ; Montefiori DC; Ferrari G; Horton H; Tomaras GD; Gurunathan S; Baglyos L; Frey SE; Mulligan MJ; Harro CD; Buchbinder SP; Baden LR; Blattner WA; Koblin BA; Corey L;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):203-12. PubMed ID: 17106277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
    Forthal DN; Gilbert PB; Landucci G; Phan T
    J Immunol; 2007 May; 178(10):6596-603. PubMed ID: 17475891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
    Salmon-CĂ©ron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
    AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
    VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S
    J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.